Sunesis Pharmaceuticals Inc (SNSS):企業の財務・戦略的SWOT分析

◆英語タイトル:Sunesis Pharmaceuticals Inc (SNSS) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15774
◆発行会社(調査会社):GlobalData
◆発行日:2019年4月
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥40,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Sunesis Pharmaceuticals Inc (SNSS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company’s Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). It is a first-in-class anti-cancer quinolone derivative that has not been used previously for the treatment of cancer. The drug candidate is also being evaluated in Phase III clinical trials for the treatment of myelodysplastic syndromes (MDS). Its other products under pipeline include TAK-580 and SNS-510 for solid tumors, and Vecabrutinib (SNS-062) for B-cell malignancies. The company collaborates with pharmaceutical companies such as Biogen, Millennium Pharmaceuticals, Inc. and Sumitomo Dainippon to obtain licenses to develop certain products. Sunesis is headquartered in South San Francisco, California, the US.

Sunesis Pharmaceuticals Inc Key Recent Developments

Mar 07,2019 Sunesis Pharmaceuticals reports fourth quarter and full-year 2018 financial results and recent highlights
Jan 02,2019 Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
Nov 05,2018 Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights
Aug 07,2018 Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Sunesis Pharmaceuticals Inc – Key Facts
Sunesis Pharmaceuticals Inc – Key Employees
Sunesis Pharmaceuticals Inc – Key Employee Biographies
Sunesis Pharmaceuticals Inc – Major Products and Services
Sunesis Pharmaceuticals Inc – History
Sunesis Pharmaceuticals Inc – Company Statement
Sunesis Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Sunesis Pharmaceuticals Inc – Business Description
Sunesis Pharmaceuticals Inc – Corporate Strategy
Sunesis Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Sunesis Pharmaceuticals Inc – Strengths
Sunesis Pharmaceuticals Inc – Weaknesses
Sunesis Pharmaceuticals Inc – Opportunities
Sunesis Pharmaceuticals Inc – Threats
Sunesis Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 07, 2019: Sunesis Pharmaceuticals reports fourth quarter and full-year 2018 financial results and recent highlights
Jan 02, 2019: Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
Nov 05, 2018: Sunesis Pharmaceuticals reports third quarter 2018 financial results and recent highlights
Aug 07, 2018: Sunesis Pharmaceuticals reports second quarter 2018 financial results and recent highlights
Jul 09, 2018: Sunesis Pharmaceuticals Announces Senior Management Changes
May 08, 2018: Sunesis Pharmaceuticals Announces First Quarter 2018 Financial Results
Mar 08, 2018: Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights
Feb 07, 2018: Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Sunesis Pharmaceuticals Inc, Key Facts
Sunesis Pharmaceuticals Inc, Key Employees
Sunesis Pharmaceuticals Inc, Key Employee Biographies
Sunesis Pharmaceuticals Inc, Major Products and Services
Sunesis Pharmaceuticals Inc, History
Sunesis Pharmaceuticals Inc, Subsidiaries
Sunesis Pharmaceuticals Inc, Key Competitors
Sunesis Pharmaceuticals Inc, Ratios based on current share price
Sunesis Pharmaceuticals Inc, Annual Ratios
Sunesis Pharmaceuticals Inc, Annual Ratios (Cont...1)
Sunesis Pharmaceuticals Inc, Interim Ratios
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Sunesis Pharmaceuticals Inc, Performance Chart (2014 - 2018)
Sunesis Pharmaceuticals Inc, Ratio Charts
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Sunesis Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Sunesis Pharmaceuticals Inc (SNSS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Covance Inc.:企業の戦略・SWOT・財務分析
    SummaryCovance Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - …
  • Chesapeake Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Chesapeake Limited Mergers and …
  • REGiMMUNE Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' REGiMMUNE Corporation Mergers a …
  • Next Plc:企業の戦略・SWOT・財務情報
    Next Plc - Strategy, SWOT and Corporate Finance Report Summary Next Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Pearl Oriental Oil Limited (formerly Pearl Oriental Innovation Limited):企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Pearl Oriental Oil Limited (for …
  • JSC “National Media Group”:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' JSC "National Media Group" Merg …
  • Lawson Software, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Lawson Software, Inc. Mergers a …
  • Ampio Pharmaceuticals Inc (AMPE):製薬・医療:M&Aディール及び事業提携情報
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • Sensimed AG:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Sensimed AG Mergers and Acquisi …
  • West Hawk Development Corp.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' West Hawk Development Corp. Mer …
  • High Peak Royalties Limited (HPR):企業のM&A・提携動向(エネルギー分野)
    Summary High Peak Royalties Limited (High Peak) formerly, Torrens Energy Limited is an upstream geothermal exploration company. The company is focused on the identification and development of geothermal resources for power generation. The company’s portfolio includes Surat Basin CSG Project, Tintabu …
  • LifeVantage Corporation (LFVN):企業の財務及び戦略的SWOT分析
    Summary LifeVantage Corporation (LifeVantage) is a nutraceutical company that manufactures, markets and distributes dietary supplements and products. The company’s product portfolio includes protandim antioxidant, canine health and TrueScience Anti-Aging cream. Its canine health is a daily supplemen …
  • Bio-Light – Israeli Life Sciences Investments Ltd. (BOLT):(医療機器分野)企業M&A及び提携動向
    Summary Bio-Light - Israeli Life Sciences Investments Ltd. (Bio-Light) is a biotechnology company. The company invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions. It operates through portfolio companies Micromedic and XLVision. Bio-L …
  • Sequella Inc:企業のM&A・提携動向(医療機器分野)
    Summary Sequella Inc (Sequella) is a clinical-stage pharmaceutical company that develops and commercializes small molecule and natural product-based therapeutics for the treatment of infectious diseases. The company’s product pipeline comprises SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid an …
  • Alcobex Metals, Ltd.の企業概要及び財務/SWOT分析
    Alcobex Metals, Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly …
  • La Plata Electric Association, Inc.:企業の発電所・SWOT分析2018
    La Plata Electric Association, Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Fujita Kanko Inc:企業の戦略・SWOT・財務情報
    Fujita Kanko Inc - Strategy, SWOT and Corporate Finance Report Summary Fujita Kanko Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cardif Lux Vie S.A.:企業の戦略・SWOT・財務情報
    Cardif Lux Vie S.A. - Strategy, SWOT and Corporate Finance Report Summary Cardif Lux Vie S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Trinidad Drilling Ltd. (TDG):企業のM&A・提携動向(石油・ガス分野)
    Summary Trinidad Drilling Ltd. (Trinidad Drilling) is an oil and gas company that offers land and barge drilling, and coring and presetting services. The company’s services include drilling, well servicing, rig fleet, coring and pre-setting, and manufacturing and technology. Its in-house manufacturi …
  • Affimed GmbH (AFMD):企業財務及び戦略的SWOT分析
    Summary Affimed GmbH(Affimed) formerly Affimed Therapeutics AG is a clinical stage biopharmaceutical company that discovers and develops targeted cancer immunotherapies. The company’s pipeline product candidates AFM11, AFM12, AFM13, AFM21 and AFM22 are unencumbered. Its product AFM13 in Phase I tria …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆